GlycoEra AG Alternatives & Competitors
12 companies similar to GlycoEra AG — Advancing Glycan Mediated Therapy
Companies similar to GlycoEra AG
Entelexo Biotherapeutics
Entelexo has created a novel platform technology for engineering exosomes as a new approac...
Irvine, United States
Hummingbird Bioscience
Hummingbird Bioscience is a biotherapeutics company working at the interface of AI and hum...
Singapore, Singapore
Dianthus Therapeutics, Inc.
Building a leading biotech company focused in severe autoimmune diseases.
United States
Rival Readout
Competing with GlycoEra AG? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Nkarta, Inc.
A New Way Forward for Autoimmune Disease
South San Francisco, Unit...
Adendra Therapeutics
Translating dendritic cell biology into new therapies for cancer and autoimmunity.
London, United Kingdom
Tridek-One
We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseas...
Paris, France
Fate Therapeutics Inc.
Transforming the lives of patients with autoimmune diseases and cancer.
San Diego, United States
Kynexis
Kynexis is advancing the first potential precision medicine for the treatment of CIAS.
Incyclix Bio
Regaining Cell Cycle Control
Durham, United States
Dyne Therapeutics
Advancing life-transforming therapies for serious muscle diseases
Waltham, United States
Lumos Pharma
Transforming Lives with Rare Focus
Austin, United States
About GlycoEra AG
GlycoEra AG, headquartered in Switzerland, is at the forefront of the biotechnology sector with its slogan, "Advancing Glycan Mediated Therapy." Founded in 2020, the company is pioneering a novel approach to treating autoimmune diseases by developing biologics targeted at specific circulating proteins, known as autoant...
Development of precision therapeutics for autoimmune diseases, Selective degradation of pathogenic proteins, Extracellular biologics platform advancement
Patients with autoimmune diseases, Healthcare providers treating autoimmune disorders, Pharmaceutical partners interested in precision immunology
Glycan Mediated Therapy, Autoimmune Disease Treatment, Extracellular Protein Degraders, Targeted Biologics Development, Selective Autoantibody Degradation, Improved Safety Profile Therapies, Early Disease Intervention, BiND™ Platform, Glycoengineering, CustomGlycan Platform, Glycan-Mediated Biology, Biopharmaceutical Development, Therapeutic Product Innovation, CMC Development (Chemistry, Manufacturing, And Controls)
B2B
Licensing, Performance Based, Service Fee
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around GlycoEra AG: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at GlycoEra AG on 9 Jun 2026. The 12 companies listed here were last checked between 7 Jun 2025 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
